Skip to main content
SpringerLink
Log in

Oncology—Lymphoma

  • Chapter
Clinical PET and PET/CT

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Bibliography

  1. A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329(14):987–94.

    Google Scholar 

  2. Alavi A, Gupta N, Alberini JL, et al. Positron emission tomography imaging in nonmalignant thoracic disorders. Semin Nucl Med 2002; 32(4):293–321.

    Article  PubMed  Google Scholar 

  3. Bar-Shalom R, Yefremov N, Haim N, et al. Camera-based FDG PET and 67Ga SPECT in evaluation of lymphoma: comparative study. Radiology 2003; 227(2):353–60.

    PubMed  Google Scholar 

  4. Dizendorf EV, Baumert BG, von Schulthess GK, et al. Impact of whole-body 18F-FDG PET on staging and managing patients for radiation therapy. J Nucl Med 2003; 44(1):24–9.

    PubMed  Google Scholar 

  5. Elstrom R,Guan L, Baker G, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 2003; 101(10):3875–6.

    Article  PubMed  CAS  Google Scholar 

  6. Filmont JE, Czernin J, Yap C, et al. Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation. Chest 2003; 124(2):608–13.

    Article  PubMed  Google Scholar 

  7. Freudenberg LS, Antoch G, Schutt P, et al. FDG-PET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging 2004; 31:325–9.

    Article  PubMed  CAS  Google Scholar 

  8. Friedberg JW, Chengazi V. PET scans in the staging of lymphoma: current status. Oncologist 2003; 8(5):438–47.

    Article  PubMed  Google Scholar 

  9. Guay C, Lepine M, Verreault J, Benard F. Prognostic value of PET using 18F-FDG in Hodgkin’s disease for posttreatment evaluation. J Nucl Med 2003; 44(8):1225–31.

    PubMed  Google Scholar 

  10. Hoffmann M, Kletter K, Diemling M, et al. Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. Ann Oncol 1999; 10(10):1185–9.

    Article  PubMed  CAS  Google Scholar 

  11. Hong SP, Hahn JS, Lee JD, et al. 18F-fluorodeoxyglucose-positron emission tomography in the staging of malignant lymphoma compared with CT and 67Ga scan. Yonsei Med J 2003; 44(5):779–86.

    PubMed  Google Scholar 

  12. Hustinx R, Lemaire C, Jerusalem G, et al. Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG. J Nucl Med 2003; 44(4):533–9.

    PubMed  CAS  Google Scholar 

  13. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin 2003;53(1):5–26.

    Article  PubMed  Google Scholar 

  14. Jerusalem G, Beguin Y, Fassotte MF, et al. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin’s disease. Ann Oncol 2003; 14(1):123–30.

    Article  PubMed  CAS  Google Scholar 

  15. Jerusalem G, Beguin Y, Najjar F, et al. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin’s lymphoma (NHL). Ann Oncol 2001; 12(6):825–30.

    Article  PubMed  CAS  Google Scholar 

  16. Kostakoglu L, Coleman M, Leonard JP, et al. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin’s disease. J Nucl Med 2002; 43(8):1018–27.

    PubMed  Google Scholar 

  17. Kostakoglu L, Leonard JP, Kuji I, et al. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma. Cancer 2002; 94(4):879–88.

    Article  PubMed  Google Scholar 

  18. Lavely WC, Delbeke D, Greer JP, et al. FDG PET in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after first-line chemotherapy. Int J Radiat Oncol Biol Phys 2003; 57(2):307–15.

    Article  PubMed  Google Scholar 

  19. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol 1989; 7(11):1630–6.

    PubMed  CAS  Google Scholar 

  20. Moog F, Bangerter M, Diederichs CG, et al. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology 1998; 206(2):475–81.

    PubMed  CAS  Google Scholar 

  21. Nakahara T, Fujii H, Ide M, et al. FDG uptake in the morphologically normal thymus: comparison of FDG positron emission tomography and CT. Br J Radiol 2001; 74(885):821–4.

    PubMed  CAS  Google Scholar 

  22. Naumann R, Beuthien-Baumann B, Reiss A, et al. Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin’s lymphoma. Br J Cancer 2004; 90(3):620–5.

    Article  PubMed  CAS  Google Scholar 

  23. O’Doherty MJ, Macdonald EA, Barrington SF, et al. Positron emission tomography in the management of lymphomas. Clin Oncol (R Coll Radiol) 2002; 14(5):415–26.

    CAS  Google Scholar 

  24. Reddy MP, Graham MM. FDG positron emission tomographic imaging of thoracic Castleman’s disease. Clin Nucl Med 2003; 28(4):325–6.

    Article  PubMed  Google Scholar 

  25. Reske SN. PET and restaging of malignant lymphoma including residual masses and relapse. Eur J Nucl Med Mol Imaging 2003; 30Suppl 1:S89–96.

    PubMed  Google Scholar 

  26. Rini JN, Leonidas JC, Tomas MB, Palestro CJ. 18F-FDG PET versus CT for evaluating the spleen during initial staging of lymphoma. J Nucl Med 2003; 44(7):1072–4.

    PubMed  Google Scholar 

  27. Schiepers C, Filmont JE, Czernin J. PET for staging of Hodgkin’s disease and non-Hodgkin’s lymphoma. Eur J Nucl Med Mol Imaging 2003; 30Suppl 1:S82–8.

    PubMed  CAS  Google Scholar 

  28. Schoder H, Larson SM, Yeung HW. PET/CT in oncology: integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies. J Nucl Med 2004; 45Suppl 1:72S–81S.

    PubMed  Google Scholar 

  29. Schoder H, Meta J, Yap C, et al. Effect of whole-body (18)F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma. J Nucl Med 2001; 42(8):1139–43.

    PubMed  CAS  Google Scholar 

  30. Schot B, van Imhoff G, Pruim J, et al. Predictive value of early 18F-fluoro-deoxyglucose positron emission tomography in chemosensitive relapsed lymphoma. Br J Haematol 2003; 123(2):282–7.

    Article  PubMed  Google Scholar 

  31. Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 2003; 102(1):53–9.

    Article  PubMed  CAS  Google Scholar 

  32. Spaepen K, Stroobants S, Dupont P, et al. Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma. Ann Oncol 2002; 13(9):1356–63.

    Article  PubMed  CAS  Google Scholar 

  33. Sutinen E, Jyrkkio S, Varpula M, et al. Nodal staging of lymphoma with whole-body PET: comparison of. J Nucl Med 2000; 41(12):1980–8.

    PubMed  CAS  Google Scholar 

  34. Tatsumi M, Kitayama H, Sugahara H, et al. Whole-body hybrid PET with 18F-FDG in the staging of non-Hodgkin’s lymphoma. J Nucl Med 2001; 42(4):601–8.

    PubMed  CAS  Google Scholar 

  35. Torizuka T, Nakamura F, Kanno T, et al. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin’s lymphoma and Hodgkin’s lymphoma. Eur J Nucl Med Mol Imaging 2004; 31(1):22–8.

    Article  PubMed  Google Scholar 

  36. Wirth A, Seymour JF, Hicks RJ, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin’s disease and non-Hodgkin’s lymphoma. Am J Med 2002; 112(4):262–8.

    Article  PubMed  Google Scholar 

  37. Wittram C, Fischman AJ, Mark E, et al. Thymic enlargement and FDG uptake in three patients: CT and FDG positron emission tomography correlated with pathology. AJR Am J Roentgenol 2003; 180(2):519–22.

    PubMed  Google Scholar 

  38. Zijlstra JM, Hoekstra OS, Raijmakers PG, et al. 18FDG positron emission tomography versus 67Ga scintigraphy as prognostic test during chemotherapy for non-Hodgkin’s lymphoma. Br J Haematol 2003; 123(3):454–62.

    Article  PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer-Verlag London Limited

About this chapter

Cite this chapter

(2005). Oncology—Lymphoma. In: Clinical PET and PET/CT. Springer, London. https://doi.org/10.1007/1-84628-100-8_14

Download citation

  • DOI: https://doi.org/10.1007/1-84628-100-8_14

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-85233-838-1

  • Online ISBN: 978-1-84628-100-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation